The estimated Net Worth of Elizabeth M Keiley is at least $244 Thousand dollars as of 19 October 2021. Ms Keiley owns over 3,759 units of Entasis Therapeutics Inc stock worth over $101,268 and over the last 10 years she sold ETTX stock worth over $143,007.
Ms has made over 4 trades of the Entasis Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently she sold 3,759 units of ETTX stock worth $11,991 on 19 October 2021.
The largest trade she's ever made was exercising 11,185 units of Entasis Therapeutics Inc stock on 20 March 2017 worth over $9,060. On average, Ms trades about 1,156 units every 84 days since 2015. As of 19 October 2021 she still owns at least 46,241 units of Entasis Therapeutics Inc stock.
You can see the complete history of Ms Keiley stock trades at the bottom of the page.
Elizabeth M. Keiley is the Gen. Counsel at Entasis Therapeutics Inc.
Ms Keiley is 55, she's been the Gen. Counsel of Entasis Therapeutics Inc since . There are 2 older and 3 younger executives at Entasis Therapeutics Inc. The oldest executive at Entasis Therapeutics Holdings Inc is Dr. John Patrick Mueller Ph.D., 61, who is the Chief Devel. Officer.
Elizabeth's mailing address filed with the SEC is C/O ENTASIS THERAPEUTICS HOLDINGS INC.,, 35 GATEHOUSE DRIVE, WALTHAM, MA, 02451.
Over the last 6 years, insiders at Entasis Therapeutics Inc have traded over $348,925 worth of Entasis Therapeutics Inc stock and bought 50,891,639 units worth $170,673,776 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Inc.Innoviva Strategic Oppo..., and Holdings A/S Novo. On average, Entasis Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of $4,855,580. The most recent stock trade was executed by Inc.Innoviva Strategic Oppo... on 8 July 2022, trading 19,270,476 units of ETTX stock currently worth $42,395,047.
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections).
Entasis Therapeutics Inc executives and other stock owners filed with the SEC include: